Molecular Announces License Deal With Novartis For At Least Up To $580 Mln
14/12 08:03
(RTTNews) - Molecular Partners AG (MOLN), a company focused on a new class of custom-built protein drugs- DARPin therapeutics, said on Tuesday that it has entered into a license agreement with Novartis AG (NVS), to make and sell DARPin-conjugated radioligand therapies or DARPin-R...